CNIC identifies key mechanism in fat cells to combat obesity
CNIC researchers have identified a mechanism in fat cells that helps them safely store excess fat, offering new insights for combating obesity and related metabolic diseases.
List view / Grid view
CNIC researchers have identified a mechanism in fat cells that helps them safely store excess fat, offering new insights for combating obesity and related metabolic diseases.
The novel strategy demonstrates a strong immune response, both body-wide and specifically in the upper respiratory tract, in porcine models.
A biomaterial that improved hyaline cartilage repair could be used to avoid knee replacements and treat injuries and degenerative diseases.
Researchers utilised AI to identify genes that reprogramme GBM cancer cells into dendritic cells within the tumour.
Mice with rod-specific VPS35 deletion demonstrate a pathology more similar to human Parkinson’s disease, compared to other mouse models.
The new study provides proof of principle that functional liver cells can be grown in a different species, offering a potential solution to transplant shortage.
Through in vitro and in vivo models, researchers find a mechanism by which bacteria-generated fatty acids regulate immune responses.
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
The new study found T3s treatment exhibited neuroprotective effects in HFSD-fed mice by mitigating oxidative stress.
The compound 11c demonstrates an excellent safety profile and is an exciting advancement in liver disease management.
In this Q&A, Dr Nicholas Waters, Head of R&D at IRLAB, shares how three compounds, including IRLABs Mesdopetam and an experimental dopamine D3 receptor antagonist, could reverse features associated with the psychosis-like state of Parkinson’s disease.
Mutation in two copies of the IKBKB gene leads to abnormal function of regulatory T cells, causing psoriatic arthritis.
In this Q&A, Dr Vidmantas Šakalys, CEO of Vital3D, provides insights into the potential of 3D bioprinting to revolutionise the traditional drug development process, facilitating more accurate models and limiting the use of animal testing.
An intravenous treatment to block lnc-HLX-2-7 from binding to the HLX promoter shrunk medulloblastoma tumours, prolonging survival in mice.
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.